Imricor Medical Systems Inc (ASX: IMR) Share Price and News
Price
$1.41
Movement
0.02 (+1.44%)
as at 14 Mar - Closed (20 mins delayed)
52 Week Range
$0.41 - $1.70
1 Year Return
+179.21%
Imricor Medical Systems Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$1.41
Day Change
0.02 (+1.44%)
52 Week Range
$0.41 - $1.70
Yesterday's Close
$1.39
Today's Open
$1.40
Days Range
$1.35 - $1.46
Volume
215,713
Avg. Volume (1 month)
309,411
Turnover
$306,357
as at 14 Mar - Closed
Should you invest $1,000 in Berkshire Hathaway right now?
Before you buy Berkshire Hathaway shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys...
See The 5 Stocks *Returns as of 6 March 2025
Imricor Medical Systems Inc (ASX: IMR)
Latest News

Share Gainers
Why Brainchip, Imricor, Strike Energy, and Wildcat shares are rising today

Share Gainers
Why Imricor, Maas, Resolute Mining, and Select Harvests shares are charging higher

Share Gainers
Why DroneShield, Imricor, IAG, and Sayona Mining shares are roaring higher

Share Market News
ASX healthcare stock rockets 25% on big AI news

Healthcare Shares
Here's why the Imricor Medical (ASX:IMR) share price is surging 8% today

Healthcare Shares
Imricor Medical (ASX:IMR) share price spikes 6% after expanding trial sites

Share Market News
Why the Imricor (ASX:IMR) share price is racing 6% higher today

Healthcare Shares
Imricor (ASX:IMR) share price rises on latest update

Share Market News
Why the Imricor (ASX:IMR) share price is edging higher today
IMR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
7th Mar 2025 2025-03-07T17:01:18 | S&P DJI Announces March 2025 Quarterly Rebalance | YesNo | 5:01pm | 8 | 179k |
4th Mar 2025 2025-03-04T09:27:46 | Submission of Second Module to FDA for PMA Products | YesNo | 9:27am | 2 | 241k |
27th Feb 2025 2025-02-27T08:07:35 | FY24 Results Investor Presentation | YesNo | 8:07am | 41 | 3.8M |
27th Feb 2025 2025-02-27T08:07:20 | Imricor Releases FY24 Results | YesNo | 8:07am | 4 | 844k |
27th Feb 2025 2025-02-27T08:06:55 | Appendix 4E and FY24 Financial Accounts | YesNo | 8:06am | 38 | 1.3M |
19th Feb 2025 2025-02-19T09:16:18 | CE Mark Approval for 2nd Gen Vision MR Ablation Catheter | YesNo | 9:16am | 2 | 240k |
17th Feb 2025 2025-02-17T09:25:39 | FY24 Results Webinar | YesNo | 9:25am | 2 | 238k |
7th Feb 2025 2025-02-07T13:21:43 | Cleansing Notice | YesNo | 1:21pm | 3 | 215k |
7th Feb 2025 2025-02-07T13:16:18 | Application for quotation of securities - IMR | YesNo | 1:16pm | 6 | 16k |
31st Jan 2025 2025-01-31T10:01:34 | Release from Voluntary Escrow | YesNo | 10:01am | 2 | 229k |
About Imricor Medical Systems Inc
Imricor Medical Systems Inc is a medical device company engaged in addressing issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. Its principal business activities are to design, manufacture and sell MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The products of the company include Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode.
IMR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
14 Mar 2025 | $1.41 | $0.02 | 1.44% | 215,713 | $1.40 | $1.46 | $1.35 |
13 Mar 2025 | $1.39 | $0.04 | 2.96% | 256,125 | $1.39 | $1.43 | $1.36 |
12 Mar 2025 | $1.35 | $0.01 | 0.74% | 225,531 | $1.35 | $1.37 | $1.30 |
11 Mar 2025 | $1.35 | $-0.16 | -10.63% | 461,765 | $1.44 | $1.44 | $1.33 |
10 Mar 2025 | $1.51 | $-0.06 | -3.85% | 334,057 | $1.56 | $1.56 | $1.45 |
07 Mar 2025 | $1.56 | $-0.03 | -1.89% | 302,866 | $1.56 | $1.61 | $1.55 |
06 Mar 2025 | $1.59 | $0.09 | 6.00% | 144,831 | $1.55 | $1.60 | $1.51 |
05 Mar 2025 | $1.50 | $0.09 | 6.36% | 480,033 | $1.42 | $1.52 | $1.42 |
04 Mar 2025 | $1.42 | $-0.17 | -10.76% | 377,907 | $1.60 | $1.61 | $1.42 |
03 Mar 2025 | $1.58 | $0.00 | 0.00% | 154,967 | $1.59 | $1.61 | $1.54 |
28 Feb 2025 | $1.58 | $0.01 | 0.63% | 274,074 | $1.59 | $1.63 | $1.49 |
27 Feb 2025 | $1.58 | $0.12 | 8.22% | 274,996 | $1.45 | $1.58 | $1.39 |
26 Feb 2025 | $1.46 | $-0.19 | -11.52% | 467,924 | $1.67 | $1.68 | $1.45 |
25 Feb 2025 | $1.65 | $0.06 | 3.77% | 120,480 | $1.61 | $1.70 | $1.60 |
24 Feb 2025 | $1.59 | $0.00 | 0.00% | 366,390 | $1.60 | $1.69 | $1.55 |
21 Feb 2025 | $1.59 | $0.07 | 4.61% | 240,021 | $1.53 | $1.59 | $1.53 |
20 Feb 2025 | $1.52 | $-0.02 | -1.30% | 309,186 | $1.55 | $1.59 | $1.50 |
19 Feb 2025 | $1.54 | $0.06 | 4.05% | 272,957 | $1.50 | $1.55 | $1.50 |
18 Feb 2025 | $1.48 | $0.07 | 4.96% | 214,637 | $1.45 | $1.51 | $1.45 |
17 Feb 2025 | $1.41 | $-0.04 | -2.76% | 593,531 | $1.47 | $1.55 | $1.41 |
14 Feb 2025 | $1.45 | $0.14 | 10.69% | 315,933 | $1.31 | $1.46 | $1.31 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
06 Jun 2024 | Steve Wedan | Issued | 2,113,342 | $951,003 |
Issue of options.
|
22 May 2024 | Steve Wedan | Buy | 100,000 | $45,000 |
Off-market trade. CDIs
|
21 May 2024 | Mark Tibbles | Issued | 107,556 | $47,862 |
Issue of securities. CDIs
|
21 May 2024 | Anita Messal | Issued | 100,834 | $44,871 |
Issue of securities.
|
21 May 2024 | Peter McGregor | Issued | 107,556 | $47,862 |
Issue of securities. CDI
|
07 May 2024 | Peter McGregor | Buy | 100,000 | $48,368 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Peter McGregor | Non-Executive Director | May 2019 |
Mr McGregor has over 30 years of experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. Mr McGregor is an experienced company director, and currently serves as a Director of Treasury Corporation of Victoria and True Infrastructure Management Pty Ltd.
|
Mr Steve Wedan | Chief Executive OfficerPresidentExecutive ChairmanExecutive Director | May 2006 |
Mr Wedan is responsible for the overall management and strategic direction of the Company. Mr Wedan has over 30 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, Mr Wedan founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006. Mr Wedan is a member of various international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. Mr Wedan currently serves on the Board of Directors of Medical Device Research Forum, Inc. and Water Rescue Innovations, Inc., as well as the Advisory Board of Poiesis Medical, LLC.
|
Mr Mark Tibbles | Non-Executive Deputy ChairmanNon-Executive Director | Sep 2014 |
Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. Mr Tibbles is currently a Board member of OMEDZA.com, Inc., FamGenix, and CorVent Medical, Inc.; an owner and managing member of STEM Fuse, LLC, one of the providers of digital K-12 STEM curriculum in the U.S.; and the Managing Director of Strategic Stage Ventures, LLC. Prior to his current roles, Mr Tibbles was a Board member of the Nerdery, LLC as well as an owner and member of Intuitive Technology Group until it was sold in 2017. Mr Tibbles was also a President and founder of PRC Consulting, Inc., a company specialising in the management and implementation of IT projects for Fortune 1000 Companies, from 1998 until 2013, when PRC was sold. He is member of Risk Committee.
|
Ms Anita Messal | Non-Executive Director | Mar 2021 |
Ms Messal has over 35 years of experience in the health care and benefits industry, most recently as the Chief Integration Officer at AccentCare where she was responsible for the integration of merged and acquired entities across all areas of the business. Ms Messal has experience in health plan services, health care delivery, care management, and benefits administration. She has worked with self-funded, fully insured and CMS funded care. Her customers and partners include large and mid-size employers, health plans, insurance carriers, brokers, resellers, enterprise software companies and consumers. Ms Messal has participated in fund raising from start-up through IPO and sale to strategic buyers and private equity. Anita has worked in both F100 and start up companies with experience in public, private and non-profit businesses. Her experience includes working in domestic and international markets, with time spent developing programs and partnerships in the United Kingdom and Europe. Ms Messal currently serves on the Board of Directors of Ideon. She is member of Risk Committee.
|
Mr Jeffrey Leighton | Non-Executive Director | Jul 2024 |
--
|
Mr Kobe Li | Company Secretary |
-
|
|
Gregg Stenzel | Chief Operating Officer |
-
|
|
Kobe Li | Company Secretary |
-
|
|
Kate Lindborg | Director of Clinical Affairs |
-
|
|
Greg Englehardt | Executive Director of Sales |
-
|
|
Nick Corkill | Vice President Corporate Strategy |
-
|
|
Dan Sunnarborg | Vice President of Engineering |
-
|
|
Jonathon Gut | Vice President of Finance and Chief Financial Officer |
-
|
|
Nick Twohy | Vice President of Marketing |
-
|
|
Vic Fabano | Vice President of Operations |
-
|
|
Jennifer Weisz | Vice President of Regulatory and Quality |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited <Domestic Hin A/C> | 21,527,041 | 11.44% |
HSBC Custody Nominees (Australia) Limited | 17,838,946 | 9.48% |
Warren G Herreid Ii | 9,486,098 | 5.04% |
Bnp Paribas Noms (Nz) Ltd | 9,002,900 | 4.78% |
Hsbc Custody Nominees (Australia) Limited A/C 2 | 8,544,746 | 4.54% |
Siemens Medical Solutions Usa Inc | 8,384,150 | 4.46% |
Hr Global Investments Llc | 6,879,579 | 3.66% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 4,649,106 | 2.47% |
UBS Nominees Pty Ltd | 3,333,334 | 1.77% |
Kahr Foundation | 2,950,988 | 1.57% |
Steven R Wedan | 2,693,720 | 1.43% |
Maclay Group Pty Ltd <Maclay Longhurst Family A/C> | 1,761,113 | 0.94% |
Bauer Private Equity Fund Vi Llc | 1,696,555 | 0.90% |
Matthew James Banfield | 1,461,868 | 0.78% |
Steven R Wedan & Cherri J Wedan Jt Ten | 1,427,373 | 0.76% |
Merrill Lynch (Australia) Nominees Pty Limited | 1,358,832 | 0.72% |
Ronald D Berger | 1,300,000 | 0.69% |
Pacific Premier Trust Cust Fbo Jeffrey J Quinn Ira | 1,288,462 | 0.68% |
Stojanov Investment Pty Ltd <Stojanov Family A/C> | 1,236,363 | 0.66% |
Bradica Nominees Pty Ltd <L & J Bradica S/F A/C> | 1,185,750 | 0.63% |